Warfarin is the second-most-likely drug, to cause adverse events requiring hospitalization. The use of warfarin sensitivity testing in the U.S. could avoid 85,000 serious-bleeding incidents. More in the way of personalized medicine and if you were a patient determined to have an adverse reaction...
The National Institute of Health sees the value of genetic profiles and is funding additional research. Duke University was the first client to use Expression Analysis and collaborates with the FDA and pharma for electronic submissions of data in an effort to accelerate drugs and diagnostics though...
The recent turn of events has literally put the FDA on somewhat of a hot seat... for an agency that minimally invested in technology, compared to other government entities, it is finding itself in a position of having to play "catch up" in a hurry...as evidenced with the recent turn of events...